Global Narcolepsy Therapeutics Market [By Product (Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, and Tricyclic Antidepressants); By Type (Cataplexy, Narcolepsy without Cataplexy, and Secondary Narcolepsy); and

Global Narcolepsy Therapeutics Market [By Product (Sodium Oxybate, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, and Tricyclic Antidepressants); By Type (Cataplexy, Narcolepsy without Cataplexy, and Secondary Narcolepsy); and By Regions]: Market size & Forecast, 2018 – 2025

The Global Narcolepsy Therapeutics Market is anticipated to reach over USD 3263.65 Million by 2025 according to a new research published by Polaris Market Research.

Narcolepsy is a therapeutic disorder which is categorized by prodigious daytime sleepiness as well as sudden attacks of sleep. In some cases, this chronic sleep disease can lead to an abrupt loss of muscle tone (cataplexy), leading to loss and weakness of muscle control. Some of the most common indications of narcolepsy are daytime sleepiness, hallucinations, fragmented sleep & insomnia, and sleep paralysis.

Growing incidence of narcolepsy and increasing overweight populace are the major factors estimated to drive the global narcolepsy therapeutics market growth. For instance, according to the Sleep Science journal 2017 report, it was estimated that around 1 in every 2,000 people across the globe are suffering from narcolepsy disorder. Moreover, according to the Australian Institute of Health and Welfare, around 63% of the Australian individuals who are aged over 18 years were estimated to be obese or overweight. Additionally, growing research and development activities and growing demands for effective treatment of the disease are another factors expected to boost the market growth. However, low per capita healthcare spending and lack of awareness majorly in middle income and lower-income economies is estimated to hinder the global narcolepsy therapeutics market during the forecast period.